Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,401 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SoC Clear all
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional

Lateral Ankle Treatment

NCT07751068
View directory record Official record
Conditions
Avulsion Fracture
Interventions
Prolonged Immobilization (Casting), Standard of Care (SOC)
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
5 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Terminated Phase 2 Interventional

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
NLA101, Standard of Care (SOC) chemotherapy
Biological · Drug
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

NCT05846789
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer, ER Positive, HER2 Negative Breast Cancer
Interventions
SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Atlanta, Georgia • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

NCT05932290
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Standard of care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Weeks and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 4 Interventional Results available

Intercostal Nerve Cryoablation for Postoperative Pain Management

NCT03972397
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intercostal Nerve Cryoablation, Bupivacaine liposomal injectable suspension, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional

Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer

NCT07790718
View directory record Official record
Conditions
Colon Polyp, Colorectal Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Aerobic Exercise, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Data Collection, Physical Performance Testing, Questionnaire Administration, Sigmoidoscopy, Survey Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Eccentric Muscle Training, Stimulation, and Biomarkers in SCI

NCT05337982
View directory record Official record
Conditions
Spinal Cord Injuries, Healthy
Interventions
Downhill Eccentric Treadmill Training with Electrical Stimulation
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 85 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 27, 2026, 8:13 AM EDT
Not yet recruiting Not applicable Interventional

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD)

NCT06989424
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Colonoscopy
Interventions
Magnetic Flexible Endoscope (MFE)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting No phase listed Observational

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

NCT06389097
View directory record Official record
Conditions
Prostate Cancer, Advanced Cancer
Interventions
Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed No phase listed Observational

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

NCT05541328
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 27, 2026, 8:13 AM EDT
Terminated No phase listed Observational

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

NCT05109195
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Standard of Care (SOC)
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 27, 2026, 8:13 AM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

NCT01204996
View directory record Official record
Conditions
Cancer
Interventions
CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin, CNTO888 + docetaxel
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Detroit, Michigan • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 27, 2026, 8:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

NCT02955394
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, Fulvestrant
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
Diagnostic Test · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Food Provision in Prenatal Care

NCT06711627
View directory record Official record
Conditions
Pregnancy Complications, Excessive Gestational Weight Gain
Interventions
Standard of Care (SoC), Food Provision
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
16 Years to 44 Years · Female only
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Springdale, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413
View directory record Official record
Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

Spine Radiosurgery for Symptomatic Metastatic Neoplasms

NCT05617716
View directory record Official record
Conditions
Metastatic Neoplasm to the Spine, Metastatic Neoplasm
Interventions
Conventional external beam radiation therapy dose (EBRT), Spine radiosurgery/stereotactic body radiation therapy standard dose, Spine radiosurgery/stereotactic body radiation therapy high dose
Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 27, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT07734038
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Venetoclax, Zanubrutinib
Procedure · Drug
Lead sponsor
Kerry Rogers
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Not yet recruiting Not applicable Interventional

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

NCT07414810
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
micro Sweat Test Patch (mSTP), Sweat Testing using SOC
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Weeks to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 27, 2026, 8:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

NCT01265849
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Interventions
LI, Cyclophosphamide, Indomethacin, Zinc, Surgery, Cisplatin, Radiotherapy
Biological · Drug · Dietary Supplement + 2 more
Lead sponsor
CEL-SCI Corporation
Industry
Eligibility
18 Years and older
Enrollment
928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
5
States / cities
Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 27, 2026, 8:13 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Bakersfield, California • San Diego, California • Ft. Pierce, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 8:13 AM EDT